• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Galecto Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    6/20/25 7:00:15 AM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GLTO alert in real time by email
    8-K
    false000180031500018003152025-06-182025-06-180001800315dei:FormerAddressMember2025-06-182025-06-18

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM 8-K

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): June 18, 2025

    GALECTO, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

     

    Delaware

    001-39655

    37-1957007

    (State or other jurisdiction

    of incorporation)

    (Commission

    File Number)

    (I.R.S. Employer

    Identification No.)

     

    75 State Street, Suite 100

    Boston, MA 02109

    (Address of principal executive offices, including zip code)

    (+45) 70 70 52 10

    (Registrant’s telephone number, including area code)

    Ole Maaloes Vej 3

    DK-2200 Copenhagen N

    Denmark

    (Former Name or Former Address, if Changed Since Last Report)

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each class

    Trade

    Symbol(s)

    Name of each exchange

    on which registered

    Common Stock, $0.00001 par value per share

    GLTO

    The Nasdaq Capital Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


     

    Item 5.07 – Submission of Matters to a Vote of Security Holders.

    Galecto, Inc. (the “Company”) held its annual meeting (the “Annual Meeting”) of stockholders on June 18, 2025. The following proposals were submitted to the stockholders at the Annual Meeting:

    (i)
    To elect Carl Goldfischer, M.D. and David Shapiro, M.D. as Class II members of the Board of Directors, to serve until the Company’s 2028 Annual Meeting of Stockholders and until their successors are duly elected and qualified, or until their earlier death, resignation or removal;
    (ii)
    To approve, in accordance with Nasdaq Listing Rule 5635(a), the issuance of shares of common stock upon conversion of the Series A non-voting convertible preferred stock issued to Bridge Medicines LLC on October 7, 2024 (the "Preferred Stock Conversion"); and
    (iii)
    To ratify the selection of EY Godkendt Revisionspartnerselskab as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025.

    The proposals are described in detail in the Company’s Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 30, 2025.

    The number of shares of common stock entitled to vote at the Annual Meeting was 1,322,359. The number of shares of common stock present or represented by valid proxy at the Annual Meeting was 677,821. All matters submitted to a vote of the Company’s stockholders at the Annual Meeting were approved and all director nominees were elected.

    The number of votes cast for and against and the number of abstentions and broker non-votes with respect to each matter voted upon are set forth below:

    (a)
    Election of Class II Directors.

    Director Nominee

    Votes For

    Votes Withheld

    Carl Goldfischer, M.D.

     

    219,253

     

    23,053

    David Shapiro, M.D.

    226,360

    15,946

     

    There were 435,515 broker non-votes regarding the election of directors.

    (b)
    Preferred Stock Conversion.

     

    Stockholders approved the Preferred Stock Conversion proposal. The results of the voting included 226,407 votes for, 15,099 votes against and 800 votes abstained. There were 435,515 broker non-votes for this proposal.

     

    (c)
    Ratification of the appointment of EY Godkendt Revisionspartnerselskab as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025.

    Stockholders ratified the appointment of EY Godkendt Revisionspartnerselskab as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025. The results of the voting included 660,974 votes for, 16,319 votes against and 528 votes abstained. There were no broker non-votes regarding this proposal.

     

     

     

     

     


     

    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

     

     

     

     

     

     

    Galecto, Inc.

     

     

     

     

    Date: June 20, 2025

     

    By:

    /s/ Hans T. Schambye

     

     

     

    Hans T. Schambye, M.D., Ph.D.

     

     

     

    President and Chief Executive Officer

     

     


    Get the next $GLTO alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $GLTO

    DatePrice TargetRatingAnalyst
    8/6/2021$12.00 → $7.00Outperform
    Credit Suisse
    More analyst ratings

    $GLTO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Galecto Reports First Quarter 2025 Operating and Financial Results

      BOSTON, May 08, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for oncology and liver diseases, announced its operating and financial results for the quarter ended March 31, 2025. "During the first quarter, we continued to advance GB3226, our dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets of AML," said Dr. Hans Schambye, CEO of Galecto. "We continued preclinical studies to support our planned IND submission, which remains on track for Q1 2026. To date, preclinical data have shown significant improvement in efficacy compared to current FLT3 and menin inhibitors, with activity acro

      5/8/25 4:30:00 PM ET
      $GLTO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galecto Reports Full-Year 2024 Financial Results

      Completed strategic review to focus on oncology and liver diseases with the acquisition of global rights to GB3226 (formerly BRM-1420), a dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets of AML from Bridge MedicinesGB3226 on track for IND submission in Q1 2026Phase 2 investigator-initiated trial (IIT) of GB1211 in combination with pembrolizumab (Keytruda®) in metastatic melanoma and head and neck squamous cell carcinoma continues to enroll patients BOSTON, March 19, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced its operating and financial r

      3/19/25 4:45:00 PM ET
      $GLTO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galecto to Participate in Upcoming Investor Conferences

      BOSTON, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and severe liver diseases, today announced that the Company management team will participate in the following upcoming investor conferences: Oppenheimer 35th Annual Healthcare Life Sciences ConferenceFormat: Corporate Presentation and One-on-One MeetingsDate and Time: Wednesday, February 12 at 8:40-9:10 AM   Location: Virtual A live webcast of the presentation will be available via the Upcoming Events section of the Company's investor relations website at https://ir.galecto.com/news-and-events/events. An archived replay wi

      2/6/25 8:00:00 AM ET
      $GLTO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GLTO
    SEC Filings

    See more
    • Galecto Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Galecto, Inc. (0001800315) (Filer)

      6/20/25 7:00:15 AM ET
      $GLTO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Galecto Inc.

      10-Q - Galecto, Inc. (0001800315) (Filer)

      5/8/25 4:00:18 PM ET
      $GLTO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Galecto Inc.

      DEFA14A - Galecto, Inc. (0001800315) (Filer)

      4/30/25 4:00:04 PM ET
      $GLTO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GLTO
    Leadership Updates

    Live Leadership Updates

    See more
    • Galecto Strengthens Board of Directors with Appointment of Dr. Amy Wechsler

      BOSTON, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced the appointment of Dr. Amy Wechsler to its Board of Directors. Dr. Wechsler brings a unique combination of expertise and a proven track record of leadership in the healthcare industry. "We are thrilled to welcome Dr. Wechsler to our Board of Directors," said Dr. Carl Goldfischer, Chair of the Board of Galecto. "Amy is a distinguished physician who has board certification in both dermatology and psychiatry. Her experience guiding companies through critical growth stages make her an important add

      10/15/24 8:30:00 AM ET
      $GLTO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galecto Adds Experienced Biotech Executive Stephanie Oestreich as Chief Business Officer

      BOSTON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced the appointment of a highly experienced biotech and pharmaceuticals executive Stephanie Oestreich, PhD, MPA as Chief Business Officer, a newly-created position at Galecto. Dr. Oestreich joins Galecto from Mnemo Therapeutics where she served as Vice President of Operations and Head of Alliance Management. She previously held the role of Executive Vice President at Evotec, a biotech company focusing on developing and delivering new medicines, and has previously served in a number of senior roles

      1/5/22 8:00:00 AM ET
      $GLTO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galecto Appoints Garrett Winslow as General Counsel

      BOSTON, May 11, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a NASDAQ listed biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced that Garrett Winslow has joined the Company as Senior Vice President, General Counsel. In this role, Mr. Winslow will lead the Company's legal, compliance and enterprise risk management functions, reporting to Hans Schambye, CEO. Garrett Winslow brings to Galecto over 15 years of experience working with public companies in the life sciences industry. Prior to joining Galecto, he served as the General Counsel of Spring Bank Pharmaceuticals.  He was also a partner in the Corporate and Securitie

      5/11/21 8:00:00 AM ET
      $GLTO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GLTO
    Financials

    Live finance-specific insights

    See more
    • Galecto Completes Strategic Review to Focus on Oncology and Liver Disease and Acquires Acute Myeloid Leukemia Preclinical Asset from Bridge Medicines

      Galecto will focus on cancer and liver disease, leveraging existing clinical stage asset GB1211Bolsters pipeline by obtaining global rights to BRM-1420, a novel dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets of acute myeloid leukemia (AML)BRM-1420 has the potential for enhanced clinical effectiveness compared to FLT3 inhibitors alone and has shown synergistic effects with SOC in preclinical models BOSTON, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced that, following an intensive strategic review process, Galecto has determined to f

      10/7/24 8:45:46 AM ET
      $GLTO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galecto Presents Positive Clinical Data at AASLD Showing Statistically Significant Improvements in Important Liver Parameters in Decompensated Cirrhosis Patients

      Statistically significant reductions observed in ALT, AST and GGT, supporting further development of GB1211 in severe liver diseasesFindings to be discussed in a conference call and virtual webinar today, November 8, 2022, at 8 a.m. ET BOSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical-stage biotechnology company and a world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, announced it will discuss topline data and additional analyses from its recently completed Phase 1b/2a GULLIVER-2 trial (NCT05009680), including the observed statistically significant signs of liver protection, in a conference call and virt

      11/8/22 6:00:00 AM ET
      $GLTO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galecto to Present Topline Data from GULLIVER-2 Clinical Trial Showing GB1211 Reduced Signs of Liver Impairment at AASLD's The Liver Meeting® 2022

      Late-breaking oral and poster presentations include clinical and preclinical data related to GULLIVER-2 clinical trialGalecto to host a webinar at 8:00 a.m. ET on Tuesday, November 8, 2022 to discuss expanded topline data and analysis BOSTON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical-stage biotechnology company and a world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced it will present data from its recently completed Phase 1b/2a GULLIVER-2 trial at the American Association for the Study of Liver Diseases' (AASLD) The Liver Meeting 2022 being held in Washington, D.C. on November 4-8, 2022. G

      10/31/22 8:00:00 AM ET
      $GLTO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GLTO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Dallas Jayson Donald Alexander

      4 - Galecto, Inc. (0001800315) (Issuer)

      6/20/25 7:00:12 AM ET
      $GLTO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Shapiro David

      4 - Galecto, Inc. (0001800315) (Issuer)

      6/20/25 7:00:09 AM ET
      $GLTO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Munshi Amit

      4 - Galecto, Inc. (0001800315) (Issuer)

      6/20/25 7:00:11 AM ET
      $GLTO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GLTO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Credit Suisse reiterated coverage on Galecto with a new price target

      Credit Suisse reiterated coverage of Galecto with a rating of Outperform and set a new price target of $7.00 from $12.00 previously

      8/6/21 10:59:40 AM ET
      $GLTO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Credit Suisse resumed coverage on Galecto with a new price target

      Credit Suisse resumed coverage of Galecto with a rating of Outperform and set a new price target of $12.00

      4/26/21 8:53:50 AM ET
      $GLTO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Credit Suisse Group reiterated coverage on Galecto with a new price target

      Credit Suisse Group reiterated coverage of Galecto with a rating of Outperform and set a new price target of $12.00 from $29.00 previously

      3/16/21 8:17:33 AM ET
      $GLTO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GLTO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Galecto Inc.

      SC 13G/A - Galecto, Inc. (0001800315) (Subject)

      11/7/24 3:07:49 PM ET
      $GLTO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Galecto Inc.

      SC 13G - Galecto, Inc. (0001800315) (Subject)

      11/7/24 2:55:56 PM ET
      $GLTO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Galecto Inc.

      SC 13G/A - Galecto, Inc. (0001800315) (Subject)

      8/29/24 5:59:56 PM ET
      $GLTO
      Biotechnology: Pharmaceutical Preparations
      Health Care